Explore

Rapid Read Rapid Read
Melanoma Scientist Richard Scolyer Passes Away After Battle with Brain Cancer

Melanoma Scientist Richard Scolyer Passes Away After Battle with Brain Cancer

Renowned melanoma expert and former Australian of the Year, Professor Richard Scolyer, has passed away at the age of 59 after battling brain cancer. Scolyer was a leading figure in melanoma research, contributing significantly to the understanding and treatment of the disease. He was instrumental in establishing the world's largest melanoma biobank and held leadership roles in major cancer organizations. Despite his illness, Scolyer continued his work, leaving a legacy of dedication and innovation in cancer research. His passing is a significant loss to the scientific community and those affected by melanoma.
Vox Vox
The most hopeful cancer news in years

The most hopeful cancer news in years

Why a roomful of oncologists gave a standing ovation for a line graph.
Trendline Trendline
Diakonos Oncology Presents Promising Data on DOC1021 for Glioblastoma and Melanoma at ASCO 2026

Diakonos Oncology Presents Promising Data on DOC1021 for Glioblastoma and Melanoma at ASCO 2026

Diakonos Oncology Presents Promising Data on DOC1021 for Glioblastoma and Melanoma at ASCO 2026
Rapid Read Rapid Read
New Cancer Treatments Highlighted at ASCO Conference Offer Hope and Challenges

New Cancer Treatments Highlighted at ASCO Conference Offer Hope and Challenges

At the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, researchers presented promising new cancer treatments. Highlights included a smart drug, GRWD5769, which helps immunotherapy drugs expose and attack cancer cells, showing significant tumor reduction in trials. Another breakthrough was a pill, daraxonrasib, doubling survival time for pancreatic cancer patients. Additionally, a genomic test could allow many breast cancer patients to skip chemotherapy. However, challenges remain, such as a failed blood test trial for early cancer detection and a predicted shortage of cancer care workers by 2050 due to rising cancer cases.
Rapid Read Rapid Read
Stony Brook Cancer Center Engages in Clinical Trial for Breast Cancer Vaccine

Stony Brook Cancer Center Engages in Clinical Trial for Breast Cancer Vaccine

Stony Brook Cancer Center on Long Island is participating in a clinical trial named 'Flamingo,' which is focused on developing a vaccine for patients with early-stage HER2-positive breast cancer. This trial is significant as it is the only site on Long Island recruiting patients for this study. The trial aims to explore new treatment avenues for breast cancer survivors, potentially offering a novel approach to managing and preventing the recurrence of this type of cancer. The involvement of Stony Brook Cancer Center highlights the institution's commitment to advancing cancer treatment and providing cutting-edge care to its patients.
Rapid Read Rapid Read
Memorial Sloan Kettering Cancer Center's Immunotherapy Breakthrough Offers New Hope for Colorectal Cancer Patients

Memorial Sloan Kettering Cancer Center's Immunotherapy Breakthrough Offers New Hope for Colorectal Cancer Patients

Recent clinical research conducted by Memorial Sloan Kettering Cancer Center has revealed a significant breakthrough in the treatment of colorectal cancer. The study highlights the potential of immunotherapy, specifically PD-1 inhibitors, to achieve complete tumor remission in certain colorectal cancers characterized by deficient mismatch repair (dMMR) or high microsatellite instability (MSI-H). This development is particularly noteworthy as it suggests that some patients with locally advanced rectal cancer could experience full clinical responses without the need for chemotherapy, radiation, or surgery. The implications of this research are profound, as traditional surgical treatments for rectal cancer often result in life-altering consequences, such as colostomies and long-term bowel dysfunction. If these findings are confirmed in larger trials, immunotherapy could become a new standard of care for select patients, offering a less invasive and more personalized treatment option.
Rapid Read Rapid Read
New Cancer Treatments Unveiled at ASCO Conference in Chicago

New Cancer Treatments Unveiled at ASCO Conference in Chicago

The American Society of Clinical Oncology (ASCO) annual meeting in Chicago showcased significant advancements in cancer treatment. Key highlights included a new drug, GRWD5769, which helps expose cancer cells to the immune system, and a daily pill, daraxonrasib, that doubles survival time for pancreatic cancer patients. The conference also discussed a genomic test that could allow some breast cancer patients to skip chemotherapy. These developments represent promising steps forward in cancer treatment, offering new hope for patients with previously limited options.
Rapid Read Rapid Read
Reply and IEO Collaborate on AI Models for Oncology

Reply and IEO Collaborate on AI Models for Oncology

Reply and the European Institute of Oncology (IEO) have announced a collaboration to develop and train domain-specific Large Language Models (LLMs) for oncology. This partnership combines Reply's expertise in generative models with IEO's clinical data to create models tailored for complex oncology settings. The initial focus areas include breast and urologic oncology, as well as prevention. The collaboration aims to enhance the efficiency of diagnosis and treatment pathways by leveraging AI to analyze large volumes of clinical data.
Rapid Read Rapid Read
Melanoma Research Alliance Names Stephanie Kauffman as New CEO

Melanoma Research Alliance Names Stephanie Kauffman as New CEO

The Melanoma Research Alliance (MRA) has appointed Stephanie Kauffman as its new Chief Executive Officer, effective July 1, 2026. Kauffman, who has been with MRA since 2022 as President and COO, will succeed Marc Hurlbert, who is moving to the National Kidney Foundation. Under Kauffman's leadership, MRA plans to continue its significant investment in melanoma research, focusing on innovative scientific collaborations and patient-centered initiatives. The organization has been a leading force in melanoma research, contributing to numerous therapeutic advancements.
Rapid Read Rapid Read
Mission Bio's Tapestri Platform Identifies Biomarker for AML Treatment in BLAST Trial

Mission Bio's Tapestri Platform Identifies Biomarker for AML Treatment in BLAST Trial

Mission Bio, in collaboration with Heidelberg University Hospital and other partners, has announced findings from a retrospective analysis of the phase II BLAST clinical trial for acute myeloid leukemia (AML). The study utilized the Tapestri platform to perform single-cell multiomic profiling, identifying high CXCR4 expression on residual leukemic cells as a potential predictive biomarker for the efficacy of Motixafortide treatment. The trial initially aimed to assess the addition of Motixafortide to high-dose cytarabine consolidation therapy in AML patients. Although the primary endpoint was not met, the retrospective analysis revealed that patients with high CXCR4 expression showed a significantly reduced risk of relapse when treated with Motixafortide. These findings suggest that integrating single-cell measurable residual disease profiling could enhance future AML clinical trial designs.
Rapid Read Rapid Read
New Study Challenges Immunology Principles, Offers Insights for Cancer Treatment

New Study Challenges Immunology Principles, Offers Insights for Cancer Treatment

Researchers at Baylor College of Medicine and the University of Michigan have discovered a new role for the immune system's MHC class I pathway in cancer treatment. Traditionally, MHC class I was thought to interact primarily with CD8+ T cells, but the study reveals it also plays a role in CD4+ T cell responses. This finding suggests that when cancer cells lose MHC I expression to evade CD8+ T cells, they become more vulnerable to CD4+ T cell attacks, leading to ferroptosis, a form of cell death. The research, published in Nature Immunology, indicates that this mechanism could be leveraged to develop new cancer therapies and improve outcomes in bone marrow transplantation.
Rapid Read Rapid Read
Breakthrough in Colorectal Cancer Treatment with Immunotherapy

Breakthrough in Colorectal Cancer Treatment with Immunotherapy

Researchers have announced a significant breakthrough in colorectal cancer treatment, revealing that certain tumors can be eradicated using immunotherapy alone, without the need for chemotherapy or surgery. This development, highlighted by Memorial Sloan Kettering Cancer Center, focuses on colorectal cancers with deficient mismatch repair (dMMR) or high microsatellite instability (MSI-H). Early clinical trials have shown complete tumor remission in some patients, suggesting a potential shift towards less invasive treatment options. This approach could reduce the need for surgeries, which often result in life-altering consequences such as colostomies and long-term bowel dysfunction.